by
Joanna J. Phillips;
Derick Aranda;
David W. Ellison;
Alexander R. Judkins;
Sidney E. Croul;
Daniel J Brat;
Keith L. Ligon;
Craig Horbinski;
Sriram Venneti;
Gelareh Zadeh;
Mariarita Santi;
Shengmei Zhou;
Christina L. Appin;
Stefano Sioletic;
Lisa M. Sullivan;
Maria Martinez-Lage;
Aaron E. Robinson;
William H. Yong;
Timothy Cloughesy;
Albert Lai;
Heidi S. Phillips;
Roxanne Marshall
High-grade astrocytomas (HGAs), corresponding to World Health Organization grades III (anaplastic astrocytoma) and IV (glioblastoma; GBM), are biologically aggressive, and their molecular classification is increasingly relevant to clinical management. PDGFRA amplification is common in HGAs, although its prognostic significance remains unclear. Using fluorescence in situ hybridization (FISH), the most sensitive technique for detecting PDGFRA copy number gains, we determined PDGFRA amplification status in 123 pediatric and 263 adult HGAs. A range of PDGFRA FISH patterns were identified and cases were scored as non-amplified (normal and polysomy) or amplified (low-level and high-level). PDGFRA amplification was frequent in pediatric (29.3%) and adult (20.9%) tumors. Amplification was not prognostic in pediatric HGAs. In adult tumors diagnosed initially as GBM, the presence of combined PDGFRA amplification and isocitrate dehydrogenase 1 (IDH1) R132H mutation was a significant independent prognostic factor (P = 0.01). In HGAs, PDGFRA amplification is common and can manifest as high-level and focal or low-level amplifications. Our data indicate that the latter is more prevalent than previously reported with copy number averaging techniques. To our knowledge, this is the largest survey of PDGFRA status in adult and pediatric HGAs and suggests PDGFRA amplification increases with grade and is associated with a less favorable prognosis in IDH1 mutant de novo GBMs.